Pfisterer J, Joly F, Kristensen G, Rau J, et al. Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial. J Clin Oncol 2022 Nov 4:JCO2201010. doi: 10.1200/JCO.22.01010.
PMID: 36332161